Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories

Abstract: Compounds useful in the treatment of inflammation structurally represented as wherein X is O or S and the R groups are as herein defined. The compounds are useful as anti-inflammatory and anti-arthritic agents without inhibiting prostaglandin synthesis.

Description: Field of the Invention The present invention relates to pyrazolopyrimidine and pyrimidinyl bisphosphonic esters, acids, and their pharmaceutically-acceptable salts, which are useful as anti-inflammatory and anti-arthritic agents. Background of the Invention Typically, prostaglandin synthetase activity is inhibited by non-steroidal anti-inflammatory agents and many of their actions, including side-effects, have been attributed to this inhibition of prostaglandin synthesis. US-A-4746654 discloses bisphosphonates useful as anti-inflammatory agents. AU-A-51534/85 discloses bisphosphonates useful in treating abnormal calcium and phosphorus metabolism and in treating arthritis. US-A-3638080 discloses polyphosphonates, in particular diphosphonates, useful in inhibiting anomalous deposition and mobilisation of calcium phosphate in animal tissue. DE-A-3719513 discloses diphosphonic acid derivatives useful in treatment of disorders of calcium metabolism. The alkylation of 5,7-dimethylpyrazolo[1,5-a]pyrimidines was disclosed at the American Chemical Society Spring Meeting on June 9, 1988 (PD 7244-88-021). EP-A-0354806 discloses imidazo[1,2-a]pyridines and imidazo[1,2-a]imidazoles. DE-A-3626058 discloses heteroaromatic diphosphonates bound to a diphosphonate. EP-A-0274158 discloses heterocycle-substituted diphosphonates and their use in treating abnormal calcium and phosphorus metabolism. Summary of the Invention Novel compounds according to this invention are pyrazolopyrimidine (Formula 1) and pyrimidinyl (Formula 2) bisphosphonic esters, acids, and their pharmaceutically-acceptable salts. The Formulae are wherein X is O or S; R 1 is independently selected from the group consisting of H, C 1 -C 6 alkyl, CH 2 -phenyl and phenyl, or both OR 1 on the same P are taken together along with CH 2 -CH 2 , CH 2 -CH 2 -CH 2 , or CH 2 -C(CH 3 ) 2 -CH 2 to form a heterocyclic ring having one P, two O and two or three carbon atoms; R 2 is hydrogen, C 1 -C 6 alkyl, benzoyloxy, benzyloxy, C 1 -C 6 alkoxy, C 3 -C 7 cycloalkyl, phenyl (optionally substituted with 1 to 5 halo, CN, CF 3 or C 1 -C 10 alkyl), 2-, 4- or 5-pyrimidyl, 2-, 3- or 4-pyridyl, or 1- or 2-naphthalenyl; R 3 is H, halo, NO 2 , CN, CF 3 , C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl, or phenyl; R 5 is H, C 1 -C 6 alkyl or C 3 -C 7 cycloalkyl; R 6 is H, halo, or C 1 -C 6 alkyl; R 10 is H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, or phenyl; R 11 is H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, allyl, CH 2 -phenyl, or phenyl (optionally substituted with 1 to 5 NO 2 , halos, or C 1 -C 4 alkyl); and either R 12 is H, C 1 -C 6 alkyl, or halo; and R 13 is hydrogen, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl (optionally substituted with 1 to 5 halos, CN, CF 3 , or C 1 -C 10 alkyl), 2-, 3- or 4-pyridyl, or 1- or 2-naphthalenyl; or R 12 and R 13 form a ring of 4 to 7 members having 4 to 7 carbons, 1 to 3 nitrogens, 0 to 2 oxygens, and 0 to 2 sulfurs. The novel compound possess anti-inflammatory response without suppressing the production of prostaglandin. This can be an advantage because it is known that, at high concentrations, prostaglandins are considered anti-inflammatory. The subject compounds are also useful for treating arthritis and its related symptoms such as inflammation and prevention of excessive bone regrowth and remodelling. The novel compounds may be used in humans and lower animals as a safe and effective treatment of diseases characterised by abnormal phosphate and calcium metabolism, and as a treatment of inflammation. These diseases include osteoporosis, Paget's disease, periodontal disease, rheumatoid arthritis, osteoarthritis, neuritis, bursitis, soft tissue mineralisation disorders, ankylosing spondylitis, atherosclerosis, multiple myeloma of bone, metastic bone disease, and mitral valve calcification. The compounds do not inhibit cyclooxygenase or lipoxygenase metabolism of arachidonic acid. Routes of administration of the compounds include oral, intramuscular, intravenous, transdermal, intra-articular, subcutaneous and intraperitoneal. An amount is administered such that the symptoms of inflammation or arthritis such as pain and discomfort are relieved or reduced, or mobility of the affected area is increased. A typical dosage is 0.001 mg to 1.0 g, the dose being determined by the particular mode of administration, use and frequency of administration. Detailed Description of the Invention The carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e. the prefix C 1 -C j defines the number of carbon atoms present from the integer "i" to the integer "j" inclusive. Thus, C 1 -C 3 alkyl refers to alkyl of 1-3 carbon atoms, inclusive, or methyl, ethyl, propyl, and isopropyl. With respect to the above, C 1 -C 6 alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, and isomeric forms thereof. C 3 -C 7 cycloalkyl is cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane and isomeric forms thereof. The term "halo" includes fluoro, chloro, bromo and iodo. C 1 -C 8 alkoxy is methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octooxy, and isomeric forms thereof. Pharmaceutically acceptable salts means salts useful for administering the compounds of this invention and include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, mesylate, maleate, malonate, succinate, tartrate, citric acid and the like. These salts may be in hydrated form. The pyrazolopyrimidine bisphosphonic esters, acids and derivatives (Formula 1) useful as anti-inflammatories and antiarthritics are prepared as shown in Examples 1-13. The general pyrazolopyrimidine heterocyclic ring structure can be prepared by procedures well known in the art. For example, the synthesis of pyrazolo[1,5-a]pyrimidines is described by M.H. Elnagdi, G.E.H. Elgemeie, and M.R.H. Elmoghayar in Advances in Heterocyclic Chemistry, Vol. 41, pg 319; M.R.H. Elmoghayar et al., Pyrimidine Derivatives and Related Compounds, Arch. Pharm. (Weinheim), 316, pp 697-702 (1983); and T. Novinson et al., 3-Substituted 5,7-Dimethylpyrazolo(1,5-a)pyrimidines, J. Med. Chem., 17, pp 645-48 (1974). One procedure for synthesizing the Formula 1 compounds of this invention is by dissolving the pyrazolopyrimidine in a suitable solvent (THF, pyridine or a combination of the two). This liquid is added dropwise to a -78°C THF solution, although this can also be done at 0°C, of a strong kinetic base (lithium hexamethyldisilazide or lithium diisopropyl amide) and the resulting solution is stirred for about 30 minutes at -78°C, although this can also be done at 0°C. Vinylidene diphosphonate is added either neat or in THF solution to the cold reaction, whereupon the reaction is allowed to warm to ambient temperature. Specific workup conditions are described in the examples. The synthesis of the corresponding Formula 1 acid is accomplished by either of two procedures, both of which are well known to those skilled in the art. The first is to reflux the tetraester in concentrated hydrochloric acid for 12 hours and concentrate the solution, and is illustrated by the synthesis of Compound "b" from "a" of Example 1, below. Alternatively, one can treat the tetraester with trimethylsilyl bromide followed by aqueous workup to isolate the acid. The Formula 1 compounds of this group are fluorescent and as such allow for the tracing of the compound through biological tissue. The pyrimidinyl bisphosphonic esters, acids and derivatives (Formula 2) useful as an anti-inflammatory and anti-arthritic are prepared as shown in Examples 14 and 15 (Compounds p-x). The synthesis of 4-pyrimidinones is well known to those skilled in the art. Briefly, a β-keto ester is treated with acetamidine hydrochloride in the presence of base to form the parent heterocyclic. The base can be sodium hydroxide, potassium carbonate, sodium methoxide or sodium ethoxide. The reaction can be run neat or the solvent can be ethanol or methanol. N-alkylated derivatives are synthesised by treatment of the parent compound with a nucleophile in the presence of base, such as potassium carbonate, sodium hydride or potassium fluoride. In one procedure, the Formula 2 compounds can be synthesised by reacting the alkylated pyrimidinones with a strong base, such as lithium hexamethyl disilazide or lithium diisopropyl amide, then treatment with a diphosphonate vinylidene such as ethenylidenebis-tetraethyl ester phosphonic acid or 2,2'-ethenylidene-bis(5,5-dimethyl-2,2'-dioxide-1,3,2-dioxaophosporinane). Compounds are purified either by chromatography or crystallisation. Compounds of this invention have been tested in a Delayed Type Hypersensitivity Granuloma Assay (DTH GRA) model for inflammation. This assay is described by Dunn et al, Agents and Actions, 27 :3/4 (1989), and Int. J. Immunopharmac., 12 (8):899-904 (1990). Briefly, mBSA-sensitised mice have a DTH granuloma (DTH GRA) lesion induced by subcutaneously implanting a mBSA-soaked filter which is excised after nine days. Compounds are administered to the mice to determine their effect on the lesions. The results are recorded as percent inhibition. The larger the inhibition, the more effective the compounds. Inhibition of 10 to 20% is considered to indicate anti-granuloma activity. Greater than 30% inhibition is good activity. The DTH GRA data obtained for compounds a, c, d, e, f, g, h, i, j, m, n, o, p, r, s, t, v, w and x are, respectively, 46, 26, 44, 41, 41, 44, 49, 47, 53, 41, 45, 53, 60, 17, 32, 7, 40, 13 and 6% (10 MPK, PO), for compounds k and 1 are respectively 31 and 23% (50 MPK), and for compound q is 57% (1 MPK, PO). Example 1: (3-(3-Cyano-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (a) Pyrazolo(1,5-a)pyrimidine (3.02 g, 16.2 mmol) was suspended in pyridine (40 ml) at 0°C and treated with a solution of LiHMDS (1M in THF, 18 mL, 18 mmol). After stirring at 0°C for 30 min. ethenylidenebis-tetraethyl ester phosphonic acid (hereinafter, ETE phosphonic acid) (4.86 g, 16.2 mmol) was added, the reaction warmed to 22°C, and stirred for 1 hour. It was then poured onto 10% HCI, extracted thrice with methylene chloride, dried with magnesium sulfate and stripped. The sample was purified by chromatography (ethyl acetate, ethyl acetate/acetone 3:1, 2:1, 1:1): 3.97 g (8.16 mmol, 50%) Sample solidified upon standing, m.p. 49-50°C. Example 2 : (3-(3-Cyano-5-methyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (c) 5,7-dimethyl-2-phenyl-pyrazolo(1,5-a)pyrimidine-3-carbonitrile (621 mg, 2.50 mmol) in pyridine (5.0 mL) at 0°C was treated with LiHMDS (2.6 mL, 2.6 mmol) and stirred for 30 min. The deep red solution was treated with ETE phosphonic acid (750 mg, 2.50 mmol) in THF (.5 mL). After stirring for 1 hour at 22°C, the reaction was poured onto 10% HCl. The organics were extracted with methylene chloride, then washed once each with 1N HCI, sodium bicarbonate, and brine, then dried with MgSO 4 , and stripped. The sample was purified by chromatography (methylene chloride, methylene chloride/acetone 9:1, then 1:9): 600 mg (1.09 mmol, 49%), m.p. 107°C (methyl t-butyl ether). Example 3 : (3-(3-Bromo-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (d) 3-Bromo-2,5,7-trimethyl-pyrazolo(1,5-a)pyrimidine (460 mg, 1.92 mmol) was dissolved in THF (10 mL) at 0°C and treated with LiHMDS (2.0 mL, 2.0 mmol). After stirring for 30 min., ETE phosphonic acid (576 mg, 1.92 mmol) in THF (1 mL) was added. After stirring for 1 hour at 22°C, the reaction was poured onto 10% HCI. The organics were extracted with methylene chloride, then washed once each with 1N HCI, sodium bicarbonate, and brine, then dried with MgSO 4 , and stripped. The sample was purified by chromatography (ethyl acetate, ethyl acetate/acetone 7:4): 527 mg (0.975 mmol, 51%), an oil. Example 4 : (3-(3-Nitro-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (e) 2,5,7-Trimethyl-3-nitro-pyrazolo(1,5-a)pyrimidine (900 mg, 4.36 mmol) was dissolved in pyridine (10 mL) at 0°C, then treated with LiHMDS (4.5 mL, 4.5 mmol). After stirring for 30 min., ETE phosphonic acid (1.31 g, 4.36 mmol) in THF (1 mL) was added. After stirring for 1 hour at 22°C, the reaction was poured onto 10% HCI. The organics were extracted with methylene chloride, then washed once each with 1N HCI, sodium bicarbonate, and brine, then dried with MgSO 4 , and stripped. The sample was purified by chromatography (ethyl acetate, ethyl acetate/acetone 7:4): 1.374 g (2.71 mmol, 62%), an oil. Example 5 : (3-(2-Benzoyloxy-5-methyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (f) A) Cyanoacetohydrazide (9.91 g, 0.10 mmol) and 2,4 pentanedione (10.5 mL, 0.10 mol) were heated for 30 min. in ethanol (20 mL) and acetic acid (0.5 mL). The reaction was cooled to 22°C, then treated with 1N sodium hydroxide (120 mL) and refluxed for 15 min. The stirred hot flask was titrated to neutrality with 12N HCI, then cooled overnight at 0°C. The solid was collected and recrystallized from ethanol: 8.565 g (0.0525 mol, 53%). 5,7-Dimethyl-pyrazolo[1,5-a]pyrimidine-2-ol (3.26 g, 20 mmol) in pyridine (60 mL) at 0°C was treated with LiHMDS (42 mL, 42 mmol) and stirred for 30 min. ETE phosphonic acid (6.30 g, 21 mmol) in THF (10 mL) was added and the reaction warmed to 22°C for 1 hour. The reaction was extracted thrice with 1N sodium hydroxide (20 mL) and these were washed thrice with ethyl acetate. The aqueous fraction was brought to neutrality with 12N HCI, extracted thrice with ethyl acetate, washed with brine, dried with magnesium sulfate, and stripped. The material was used without further purification in the next reaction. B) The crude pyrazolo[1,5-a]pyrimidine-2-ol (475 mg, 1.02 mmol) in methylene chloride (5 mL) at 0°C was treated with benzoyl chloride (0.12 mL, 1.02 mmol) and triethyl amine (0.17 mL, 1.2 mmol). After stirring for 1 hour, the reaction was quenched with 1N HCI, extracted thrice with ethyl acetate, then washed with sodium bicarbonate, brine, dried with magnesium sulfate, and stripped. The sample was chromatographed (ethyl acetate, ethyl acetate/acetone 1:1) and the semi-pure product crystallized upon standing. It was recrystallized with ether/hexane: 97 mg (0.17 mmol, 17%), m.p. 56-57°C. Example 6 : (3-(2-Benzyloxy-5-methyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (g) 5,7-Dimethyl-pyrazolo[1,5-a]pyrimidine-2-ol (1.63 g, 10 mmol), potassium carbonate (690 mg, 5 mmol), and DMF (6 mL) were heated to 115-120°C for 5 min., then treated with benzyl chloride (1.2 mL, 10 mmol). The reaction was stirred for 20 min. at 120°C, then poured onto excess 1N NaOH. The organics were extracted twice with ethyl acetate, then washed with sodium bicarbonate and brine, dried with magnesium sulfate, and stripped. The product crystallized when stripped from hexane, then was recrystallized from hexane with Darco: 539 mg. From the mother liquors an additional 248 mg were recovered: 787 mg (3.10 mmol, 31%). The benzyl ether (539 mg, 2.1 mmol) in THF (2 mL) at -78°C was treated with LiHMDS (2.2 mL, 2.2 mmol) and stirred for 30 min. ETE phosphonic acid (630 mg, 2.1 mmol) in THF (1 mL) was added and stirred at 22°C for 1 hour. The organics were poured onto 10% HCI, extracted thrice with ethyl acetate, washed with sodium bicarbonate and brine, dried with magnesium sulfate, and stripped. The product was isolated by chromatography (ethyl acetate, ethyl acetate/acetone 1:1): 547 mg (0.988 mmol, 47%), an oil. Example 7 : (3-(2-Hexyloxy-5-methyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (h) 5,7-Dimethyl-pyrazolo[1,5-a]pyrimidine-2-ol (1.63 g, 10 mmol), potassium carbonate (690 mg, 5 mmol), and DMF (6 mL) were heated to 115-120°C for 5 min., then treated with hexyl bromide (1.5 mL, 10.7 mmol). The reaction was stirred for 20 min. at 120°C, then poured onto excess 1N NaOH. The organics were extracted twice with ethyl acetate, then washed with 1N HCI and brine, dried with magnesium sulfate, and stripped. The product refused to crystallize: 1.876 g (7.6 mmol, 76%). The crude ether (1.876 g, 7.6 mmol) was dissolved in THF (5 mL), cooled to -78°C, and treated with LiHMDS (7.6 mL, 7.6 mmol). After stirring for 30 min., ETE phosphonic acid (2.27 g, 7.6 mmol) in a trace of THF was added and the reaction was stirred at 22°C for 1 hour. The organics were poured onto 10% HCI, extracted thrice with ethyl acetate, washed with sodium bicarbonate and brine, dried with magnesium sulfate, and stripped. The product was purified by chromatography (ethyl acetate, ethyl acetate/acetone 1:1): 1.632 g (2.98 mmol, 39%). Example 8 : (3-(5-Methyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (i) Pyrazolopyrimidine (1.00 g, 4.5 mmol) dissolved in pyridine (9 mL) was cooled to 0°C and treated with LiHMDS (4.9 mL, 4.9 mmol) and stirred for 30 min. A solution of ETE phosphonic acid (1.28 g, 4.2 mmol) in THF (4 mL) was added and the solution was stirred for an additional 30 minutes. The reaction mixture was poured into cold 10% HCI and washed three times with methylene chloride. The combined organic layers were washed with 10% HCI, H 2 O, NaHCO 3 , NaCl, dried with MgSO 4 and stripped. Chromatographed with ethyl acetate followed by 10% acetone/ethyl acetate. The resultant material solidified on standing. The solid was dissolved in ether and precipitated with hexane, m.p. 51-52°C. Recovered 0.824 g (1.57 mmol, 37%). Example 9 : (3-(3-Iodo-5-methyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (j) Compound "i" from Example 8 (0.786 g, 1.5 mmol) dissolved in chloroform (4.8 mL) was treated with N-Iodosuccinimide (0.345 g, 1.54 mmol) and refluxed for 20 min. The solution was cooled and poured onto 2N KOH (6.7 mL). The layers were separated and the chloroform was washed with water, dried with MgSO 4 and stripped. Purified by chromatography on silica gel with 2% ethanol/ethyl acetate. The material solidified upon standing, m.p. 81-82°C. Recovered 0.741 g (1.14 mmol, 76%). Example 10 : (3-(3-Chloro-5-methyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (k) Compound "i" from Example 8 (1.490 g, 2.8 mmol) in chloroform (10 mL) was treated with N-Chlorosuccinimide (0.418 g, 3.1 mmol) and refluxed for 30 min. The solution was cooled and poured onto cold 2N KOH (13 mL). Separated and washed the organic layer twice with water and NaCl. Dried with MgSO 4 and stripped then chromatographed with 2% ethanol/ethyl acetate. Product solidified upon standing, m.p. 66-68°C. Recovered 0.763 g (1.37 mmol, 49%). Example 11 : (3-(3-Bromo-5-methyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (l) Compound "i" from Example 8 (1.488 g, 2.8 mmol) in chloroform (10 mL) was treated with N-Bromosuccinimide (0.52 g, 2.9 mmol) and the solution was refluxed for 25 min. Cooled and poured onto cold 2N KOH (13 mL) and separated. Washed organic layer twice with water and with brine. Dried with MgSO 4 and stripped then chromatographed with 2% ethanol/ethyl acetate. Product solidified upon standing, m.p. 46-48°C. Recovered 1.47 g (2.44 mmol, 87%). Example 12 : (3-(3-Cyano-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bisphosphonic acid tetramethyl ester (m) Pyrazolo (1,5-a)pyrimidine (1.25 g, 6.71 mmol) in pyridine (15 mL) at 0°C was treated with LiHMDS (8.1 mL, 8.1 mmol) and stirred for 30 min. Ethenylidene bis-tetramethyl ester phosphonic acid (1.64 g, 6.71 mmol) was added, the reaction warmed to 22°C and stirred for 1 hour. The solution was poured onto 10% HCI, extracted thrice with methylene chloride, dried with magnesium sulfate and stripped. The product was recrystallized from ethyl acetate: 1.152 g (2.68 mmol, 40%), m.p. 100-101°C. Example 13 : (3-(3-Cyano-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl)-propane-1,1-diyl)bis(5,5-dimethyl-2,2'-dioxide-1,3,2-dioxaphosphorinane) (n) Pyrazolo (1,5-a)pyrimidine (1.30 g, 6.98 mmol) in pyridine (15 mL) at 0°C was treated with LiHMDS (7.1 mL, 7.1 mmol) and stirred for 30 min. Solid 1,1'-ethenylidene-bis-(5,5-dimethyl-2,2'-dioxide-1.3,2-dioxaphosphorinane) phosphonic acid (2.26 g, 6.98 mmol) was added, the reaction warmed to 22°C, and stirred for 30 min. The reaction was poured onto 10% HCI, extracted thrice with methylene chloride, dried with magnesium sulfate and stripped. The sample was recrystallized from methylene chloride/hexane: 1.743 g (3.41 mmol, 49%), m.p. 258-259°C. Example 14 : (3-(2-(3-Methyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl))-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (p) To a solution of lithium hexamethyldisilazide (1.0 M in THF, 72 ml, 72 mmol) at -78°C was added dropwise to a solution of 2,3-dimethyl-6-phenyl-pyrimidin-4(3H)one (13.064 g, 65.16 mmol) in THF (50 ml). After stirring for 30 min. at -78°C, the vinylidene diphosphonate (21.6 g, 72 mmol) was added and the reaction warmed to 22°C for 1 hour. The reaction was quenched with saturated ammonium chloride, extracted thrice with ethyl acetate, washed twice with brine, dried with magnesium sulfate, and stripped. The material was recrystallized from methyl t-butyl ether: 20.61 g (41.2 mmol, 63%), m.p. 83-84°C. Additional compounds were obtained by following this same general procedure for the following compounds. (r) (3-(2-(3-Benzyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl))-propane-1,1-diyl)bisphosphonic acid tetraethyl ester, m.p. 72-74°C; (s) (3-(2-(3-Methyl-4-oxo-6-(3-fluoro-phenyl)-4(3H)-pyrimidinyl))-propane-1,1-diyl)bisphosphonic acid tetraethyl ester, m.p. 93.5-95.5°C; (t) (3-(2-(3-Allyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl))-propane-1,1-diyl)bisphosphonic acid tetraethyl ester, m.p. 53-55°C; (u) (3-(2-(5-Bromo-3-methyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl))propane-1,1-diyl)bisphosphonic acid tetraethyl ester, oil, m/e 580, 578 (m + ), 443, 441, 293, 291, 288; (v) (3-(2-(3-Methyl-4-oxo-6-(3-methyl-phenyl)-4(3H)-pyrimidinyl))-propane-1,1-diyl)bisphosphonic acid tetraethyl ester, m.p. 90-91°C; (w) (3-(2-(3-Methyl-4-oxo-6-(3-methoxy-phenyl)-4(3H)-pyrimidinyl))-propane-1,1-diyl)bisphosphonic acid tetraethyl ester, m.p. 65-66°C; (x) (3-(2-(3-Methyl-4-oxo-6-(3-trifluoromethyl-phenyl)-4(3H)-pyrimidinyl))-propane-1,1-diyl)bisphosphonic acid tetraethyl ester, m.p. 77-79°C. Example 15 : (3-(2-(3-Methyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl))-propane-1,1-diyl)bisphosphonic acid disodium salt (q) (3-(2-(3-Methyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl))-propane-1,1-diyl)bisphosphonic acid tetraethyl ester (2.29 g, 4.58 mmol) was heated in concentrated hydrochloric acid (20 ml) at reflux for 24 hours, then the solution was stripped to dryness. The residue was suspended in water and the pH was adjusted to 7 with sodium hydroxide. The product was precipitated from the solution with methanol, filtered and air dried: 940 mg (2.17 mmol, 47%), m.p. > 300°C.

Claims: A compound of Formula 1 or 2 or a pharmaceutically-acceptable salt thereof wherein X is O or S; R 1 is independently selected from the group consisting of H, C 1 -C 6 alkyl, CH 2 -phenyl and phenyl, or both OR 1 on the same P are taken together along with CH 2 -CH 2 , CH 2 -CH 2 -CH 2 , or CH 2 -C(CH 3 ) 2 -CH 2 to form a heterocyclic ring having one P, two O and two or three carbon atoms; R 2 is hydrogen, C 1 -C 6 alkyl, benzoyloxy, benzyloxy, C 1 -C 6 alkoxy, C 3 -C 7 cycloalkyl, phenyl (optionally substituted with 1 to 5 halo, CN, CF 3 or C 1 -C 10 alkyl), 2-, 4- or 5-pyrimidyl, 2-, 3- or 4-pyridyl, or 1- or 2-naphthalenyl; R 3 is H, halo, NO 2 , CN, CF 3 , C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl, or phenyl; R 5 is H, C 1 -C 6 alkyl or C 3 -C 7 cycloalkyl; R 6 is H, halo, or C 1 -C 6 alkyl; R 10 is H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, or phenyl; R 11 is H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, allyl, CH 2 -phenyl, or phenyl (optionally substituted with 1 to 5 NO 2 , halos, or C 1 -C 4 alkyl); and either R 12 is H, C 1 -C 6 alkyl or halo; and R 13 is hydrogen, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl (optionally substituted with 1 to 5 halos, CN, CF 3 , or C 1 -C 10 alkyl), 2-, 3- or 4-pyridyl, or 1- or 2-naphthalenyl; or R 12 and R 13 form a ring of 4 to 7 members having 4 to 7 carbons, 1 to 3 nitrogens, 0 to 2 oxygens, and 0 to 2 sulfurs. The compound of claim 1, wherein R 1 is ethyl. The compound of claim 1, wherein R 2 is methyl, hydrogen or phenyl. The compound of claim 1, wherein R 3 is CN, phenyl, NO 2 , hydrogen or halo. The compound of claim 1, wherein R 5 is methyl. The compound of claim 1, wherein R 6 is hydrogen. The compound of claim 1, of Formula 1, which is: a) (3-(3-cyano-2,5-dimethylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, b) (3-(3-cyano-2,5-dimethylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid, dipotassium salt, c) (3-(3-cyano-5-methyl-2-phenylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, d) (3-(3-bromo-2,5-dimethylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, e) (3-(3-nitro-2,5-dimethylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, f) (3-(2-benzoyloxy-5-methylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, g) (3-(2-benzyloxy-5-methylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, h) (3-(2-hexyloxy-5-methylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, i) (3-(5-methyl-2-phenylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, j) (3-(3-iodo-5-methyl-2-phenylpyrazolo(1,5-a)-pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, k) (3-(3-chloro-5-methyl-2-phenylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, l) (3-(3-bromo-5-methyl-2-phenylpyrazolo(1,5-a)-pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, m) (3-(3-cyano-2,5-dimethylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester, n) (3-(3-cyano-2,5-dimethylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bis(5,5-dimethyl-2,2'-dioxide-1,3,2-dioxaphosphorinane), or o) (3-(6-chloro-3-cyano-2,5-dimethylpyrazolo(1,5-a)pyrimidin-7-yl)propane-1,1-diyl)bisphosphonic acid tetraethyl ester. The compound of claim 1, wherein X is oxygen. The compound of claim 1, wherein R 10 is hydrogen. The compound of claim 1, wherein R 11 is C 1 -C 3 alkyl. The compound of claim 1, wherein R 13 is phenyl. The compound of claim 1, wherein R 13 is phenyl substituted with a halo, methyl or CF 3 . The compound of claim 1, of Formula 2, which is: p) (3-(2-(3-methyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl)propane-1,1-diyl))bisphosphonic acid tetraethyl ester, q) (3-(2-(3-methyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl))propane-1,1-diyl)bisphosphonic acid disodium salt, r) (3-(2-(3-benzyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl)propane-1,1-diyl))bisphosphonic acid tetraethyl ester, s) (3-(2-(3-methyl-4-oxo-6-(3-fluorophenyl-4(3H)-pyrimidinyl))propane-1,1-diyl)bisphosphonic acid disodium salt, t) (3-(2-(3-allyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl)propane-1,1-diyl))bisphosphonic acid tetraethyl ester, u) (3-(2-(5-bromo-3-methyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl)propane-1,1-diyl))bisphosphonic acid tetraethyl ester, v) (3-(2-(3-methyl-4-oxo-6-(3-methylphenyl-4(3H)-pyrimidinyl)propane-1,1-diyl))bisphosphonic acid tetraethyl ester, w) (3-(2-(3-methyl-4-oxo-6-(3-methoxyphenyl-4(3H)-pyrimidinyl)propane-1,1-diyl))bisphosphonic acid tetraethyl ester, x) (3-(2-(3-methyl-4-oxo-6-(3-trifluoromethylphenyl-4(3H)-pyrimidinyl)propane-1,1-diyl))bisphosphonic acid tetraethyl ester, or y) (3-(2-(3-methyl-4-oxo-6-phenyl-4(3H)-pyrimidinyl)propane-1,1-diyl))bisphosphonic acid tetraethyl ester. Use of a compound of claim 1, for the preparation of a medicament for treatment of inflammation. The use of claim 14, wherein the medicament provides 0.001 mg to 1.0 g of the compound and is adapted for administration orally, intramuscularly, intravenously, transdermally, intra-articularly, subcutaneously or intraperitoneally.

Inventors: NUGENT RICHARD ALLEN, SCHLACHTER STEPHEN THOMAS, NUGENT, RICHARD ALLEN, SCHLACHTER, STEPHEN THOMAS
Applicants: UPJOHN CO, PHARMACIA & UPJOHN COMPANY
Application year: 1992
Main classification: C07F9
IPC codes: C07F9, A61K31, A61P29